AH

Andrew Hedin

Partner at Bessemer Venture Partners

Greater Boston

Overview 

Andrew Hedin is a Partner at Bessemer Venture Partners with a focus on biotech and healthcare investments. He has successfully invested in companies like Seismic Therapeutic and Kymera Therapeutics, demonstrating a strong track record in the industry. Hedin's career highlights include his role as a Partner at Bessemer Venture Partners and his successful investments in various biotech and healthcare companies, showcasing his expertise in venture capital within the healthcare sector.

Work Experience 

BV

Bessemer Venture Partners

  • Partner

    2015 - Current

    Focused on high growth biotech and healthcare companies Board Director @ Seismic Therapeutic, Kymera Therapeutics ($KYMR): 2018-2021, TScan Therapeutics ($TCRX): 2018-2021, Nido Biosciences, Rimsys, Peptone, Plenful, CopilotIQ Board observer and/or investor @ Curie Bio, Watershed Informatics, Collective Medical, Bright Health, Qventus, Groups, Artemis Health, AccuVein, Fractyl, Ginger/Headspace Health, Hinge Health, Inductive Bio among others

BVP Forge operates as a private equity firm that focuses on software-enabled businesses.

bvp.com
RH

Remita Health

  • Operations

    2014 - 2014

    f.k.a. Health Essentials

Remita Health provides physician-driven care management services for physically weak and elderly people.

Raised $9,506,102.00 from Bessemer Venture Partners, SV Health Investors and Bessemer Venture Partners.

remitahealth.com
FC

F-Prime Capital Partners

  • Healthcare VC

    2010 - 2013

    F-Prime Capital (f.k.a. Fidelity Biosciences) invests venture capital in private therapeutics, medtech, and health IT & services companies. Executed new and follow-on investments in the US, China, and India. Invested in private biotech and health IT companies (Series A – Series D) focused on rare diseases, cancer, ophthalmology, dermatology, HR benefits and hospital equipment.

F-Prime Capital is a venture capital firm investing in healthcare and technology.

fprimecapital.com

Leerink Partners LLC

  • Associate

    2007 - 2010

    Leerink Partners is a boutique investment bank and consulting firm focused exclusively on life sciences companies, including pharmaceutical, biotech, drug delivery and medical device companies. Leerink Consulting is the strategy consulting branch of the organization. Analyst: 2007 – 2009

University of Pennsylvania Department of Animal Biology, Neuroscience Laboratory

  • Neuroscience Research Assistant

    2006 - 2007

    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034235/ Conducted research in Tracy Bale's neuroscience lab, which focuses on developing mouse models of stress sensitivity related to neurodevelopmental and neuropsychiatric disease.

Penn Resiliency Project

  • Psychology Research Supervisor

    2004 - 2007

    The Penn Resiliency Program (PRP), designed by Penn's research team, is a group intervention for late elementary and middle school students. The curriculum teaches cognitive-behavioral and social problem-solving skills and is based in part on cognitive-behavioral theories of depression by Aaron Beck, Albert Ellis, and Martin Seligman (Abramson, Seligman, & Teasdale, 1978; Beck, 1967, 1976; Ellis, 1962). Central to PRP is Ellis' Adversity-Consequences-Beliefs (ABC) model, the notion that our beliefs about events mediate their impact on our emotions and behavior. Through this model, students learn to detect inaccurate thoughts, to evaluate the accuracy of those thoughts, and to challenge negative beliefs by considering alternative interpretations. PRP also teaches a variety of strategies that can be used for solving problems and coping with difficult situations and emotions. Students learn techniques for assertiveness, negotiation, decision-making, social problem-solving, and relaxation. The skills taught in the program can be applied to many contexts of life, including relationships with peers and family members as well as achievement in academics or other activities.

Education 

Investments 

Seismic Therapeutic

Series B

Total funding: $220M

Plenful

Seed

Total funding: $26M

Peptone

Series A

Total funding: $42M

Rimsys

Series A

Total funding: $18M

Latest Articles 

Articles About Andrew

Relevant Websites